Đang chuẩn bị liên kết để tải về tài liệu:
Evaluation of IL-2 and Dexamethasone intracavitary injection on the management of malignant efusion in children with solid tumors or lymphoma

Currently, no available coherent management protocol exists for pediatric cancers associated with pleural effusion, ascites, and pericardial efusion. This study aimed to retrospectively present our experience in treating pediatric cancer patients with pleural effusion, ascites, and pericardial efusion using interleukin-2 (IL-2) and dexa‑ methasone (DEX) intracavitary injections. | Zhang et al. BMC Cancer 2021 21 1302 https doi.org 10.1186 s12885-021-09041-7 RESEARCH Open Access Evaluation of IL-2 and Dexamethasone intracavitary injection on the management of malignant effusion in children with solid tumors or lymphoma Yu Tong Zhang1 Xiao dan Zhong1 Yan li Gao2 and Jian Chang1 Abstract Background Currently no available coherent management protocol exists for pediatric cancers associated with pleural effusion ascites and pericardial effusion. This study aimed to retrospectively present our experience in treating pediatric cancer patients with pleural effusion ascites and pericardial effusion using interleukin-2 IL-2 and dexa methasone DEX intracavitary injections. Methods Between January 1st 2008 and December 31st 2020 medical reports of patients diagnosed with solid tumors or lymphoma were checked to identify patients diagnosed with gt 2 cm pleural effusion and or more than grade 1 ascites and or more than small pericardial effusion. Patients diagnosed with effusions and treated with IL-2 and DEX were identified as being in the effusion group. Meanwhile patients with the same primary tumors and effu sions but did not receive interleukin 2 and DEX injection were reviewed and classified as the control group. Results Forty patients with solid tumors and 66 patients with lymphoma were further diagnosed with pleural effu sion ascites or pericardial effusion. A total of 85 patients received IL-2 and DEX injection while the remaining 21 did not. The Kaplan Meier analysis revealed a significant difference between the two groups with p Zhang et al. BMC Cancer 2021 21 1302 Page 2 of 8 no coherent management protocol is currently found for and pericardial effusion treatment response and patient pleural effusion ascites and pericardial effusion. It seems outcome. The Institutional Review Boards approved that pleural effusion ascites and pericardial effusion can the collection of patients clinical records. All data were only be resolved with systemic .